[Ketoconazole. 3 years' experience with a new orally active broadspectrum antimycotic].
Ketoconazole is an orally high effective broad-spectrum antimycotic of the imidazole series. It is very well tolerated and stands out by its long-lasting therapeutic serum levels, lack of development of resistant fungi, simple administration and low toxicity. Own experience has shown its high efficacy in pityriasis versicolor, mycoses due to dermatophytes, skin and mucous membrane candidoses and chronic mucocutaneous candidosis syndromes. Its effect in systemic mycoses is promising. Consistent follow-up of laboratory data did not suggest any changes due to ketoconazole even after more than one year of treatment.
D000284:Administration, Oral; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage*; D003881:Dermatomycoses / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000378:metabolism; D007654:Ketoconazole; D007700:Kinetics; D008297:Male; D051379:Mice; D010879:Piperazines / Q000008:administration & dosage* / Q000378:metabolism; D011817:Rabbits; D051381:Rats
D000935:Antifungal Agents; D007093:Imidazoles; D010879:Piperazines; D007654:Ketoconazole
Ketoconazol-3jährige Erfahrungen mit einem neuen oral wirksamen Breitspektrumantimykotikum.